Head-To-Head Comparison: Organogenesis (ORGO) versus Its Competitors
Organogenesis (NASDAQ: ORGO) is one of 606 public companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Organogenesis to related businesses based on the strength of its risk, valuation, dividends, analyst recommendations, institutional ownership, profitability and earnings.
Insider & Institutional Ownership
3.9% of Organogenesis shares are owned by institutional investors. Comparatively, 45.7% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 70.4% of Organogenesis shares are owned by insiders. Comparatively, 15.8% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Organogenesis and its peers revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Organogenesis||$260.98 million||-$40.45 million||-8.14|
|Organogenesis Competitors||$2.13 billion||$273.29 million||-0.35|
Organogenesis’ peers have higher revenue and earnings than Organogenesis. Organogenesis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
This table compares Organogenesis and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of recent recommendations for Organogenesis and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Organogenesis currently has a consensus target price of $10.00, indicating a potential upside of 192.40%. As a group, “Pharmaceutical preparations” companies have a potential upside of 79.15%. Given Organogenesis’ stronger consensus rating and higher probable upside, equities analysts plainly believe Organogenesis is more favorable than its peers.
Organogenesis beats its peers on 7 of the 12 factors compared.
Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.
Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.